Fairvalue-Calculator Fairvalue-Calculator
EN DE

Evrofarma SA (EVROF) Fair Value & Analysis

Consumer Defensive · GR · Market cap €53.6M

Price€3.76
Fair Value€0.9000
Upside-76.1%
Quality89/100
Evidence: Medium Range €0.5800 – €2.02

Fair value as of: Jun 24, 2026

Analysis

Evrofarma SA (EVROF) currently trades at €3.76, while our model-based Fair Value estimate is €0.9000 — implying the stock looks roughly 76.1% overvalued today. We read business quality at 89/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Evrofarma SA produces and sells dairy products in Greece. It offers milk, yoghurt, and cheese products, as well as fermented beverages. The company also exports its products. Evrofarma SA was founded in 1991 and is headquartered in Didymoteicho, Greece.

Open the full interactive analysis →

Similar stocks

Nestlé S.A (NESN) -36% Foshan Haitian Flavouring and Food Company (603288) -22% Nestlé India Limited (NESTLEIND) -74% Grupo Bimbo, S.A. (BIMBOA) -21% Uni-President Enterprises Corp (1216) -3% Britannia Industries Limited (BRITANNIA) -32%

Frequently asked questions

Is Evrofarma SA (EVROF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of €0.9000 versus a price of €3.76 — about −76% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EVROF?
Our 21-model fair value for Evrofarma SA is €0.9000 (as of Jun 24, 2026), built from audited fundamentals. The current price is €3.76.
What is the quality score of EVROF?
Evrofarma SA has a Quality Score of 89/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.